Scott Alexander examines the concept of 'Pascalian Medicine', weighing the pros and cons of taking multiple unproven but potentially beneficial treatments. Longer summary

Scott Alexander explores the concept of 'Pascalian Medicine', where one takes multiple unproven but safe treatments based on a small chance they might work. He discusses this in the context of COVID-19 treatments like Vitamin D and ivermectin, and extends it to other conditions. The post examines arguments for and against this approach, including safety concerns, societal impacts, and the risk of being exploited by bad actors. Scott concludes that while this strategy might work for individuals, it's problematic on a societal level, and reconciling inside and outside views on the probability of treatments working remains challenging. Shorter summary

Scott Alexander critiques the FDA's slow approval process for Paxlovid, a promising COVID-19 treatment, despite its proven effectiveness. Longer summary

Scott Alexander discusses the FDA's delay in approving Paxlovid, a highly effective COVID-19 treatment. He criticizes the FDA for taking an estimated six weeks to approve the drug despite stopping trials early due to its effectiveness. The post explores the inconsistency in the FDA's approach, questions potential reasons for the delay, and emphasizes the urgency of approval given the ongoing COVID-19 deaths. Scott also addresses potential criticisms by comparing the situation to ivermectin and acknowledging the risk of unforeseen issues with Paxlovid. Shorter summary

Scott summarizes and responds to comments on his previous article about FDA approval of Paxlovid, acknowledging some valid points while maintaining his criticism of the approval process. Longer summary

This post summarizes comments on Scott's previous article about FDA approval of Paxlovid. It covers manufacturing challenges, FDA approval processes, production capacity, ongoing studies, and ethical considerations. Scott acknowledges some valid points raised by commenters about reasons for FDA delays, but maintains his criticism of the approval process, suggesting a need for different levels of approval and questioning the current drug approval system. Shorter summary